Adding another potential wrinkle to the industry’s work with China is the Biosecure Act, a piece of China-targeting national ...

Amid news of the splashy $4.8 billion Amicus buy, BioMarin has slipped in the discontinuation of a genetic liver disease ...

One of the main threads running through our most-read stories of 2025—as much as ever in the medtech industry writ large—is ...

Windtree Therapeutics has not been shy about its desire to become a revenue-generating company, even when achieving that goal ...

Edwards Lifesciences has claimed an FDA approval for its Sapien M3 transcatheter mitral valve replacement system—marking the ...

William Blair has hand-picked its top five stock recommendations for 2026, selections that include three clinical-stage ...

Big Pharma-backed Aktis Oncology has announced plans to go public, in the latest encouraging sign for those betting on a ...

Two years after Gilead Sciences secured the first option on Assembly Biosciences’ entire pipeline, the pharma has decided to ...

Hope is preparing for close-out meetings with the FDA. Chang said the team is “hopeful to advance to a phase 3 confirmatory trial” of the stem cell therapy candidate.

Boehringer Ingelheim has opened another front in its attack on chronic kidney disease (CKD), offering Rectify Pharmaceuticals up to $448 million to partner on a preclinical program.

Six people, including a former employee of investment bank Citigroup’s San Francisco office, have been charged in an $41 million insider trading and stock manipulation scheme that involves two biotech ...

It was the best of times, it was the worst of times for research in 2025. | It was the best of times and it was the worst of times for research in 2025. Medical breakthroughs and stunning discoveries ...